DelveInsight, a leading market research and business consulting firm, has released its latest report, “Osteoporosis Market Insights, Epidemiology, and Market Forecast – 2036.” The report offers comprehensive insights into Osteoporosis epidemiology, current and emerging treatment paradigms, market trends, competitive intelligence, and forecast analysis across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Osteoporosis Market

• The Osteoporosis market across the 7MM is expected to witness robust growth through 2036, driven by increasing diagnosis rates, rising fracture incidence, and expanding therapeutic innovation.

• The United States accounted for the largest Osteoporosis market size among the 7MM in 2025, owing to high disease prevalence, strong treatment adoption, and increasing healthcare expenditure.

• According to the International Osteoporosis Foundation (2024), nearly 75 million people across Europe, the United States, and Japan are affected by osteoporosis.

• DelveInsight estimates indicate that the total diagnosed prevalent cases of Osteoporosis in the United States are expected to increase steadily during the forecast period from 2022–2036.

• According to the CDC (2021), the prevalence of low bone mass among adults aged 50 years and older was approximately 43.1%, with women accounting for nearly 60% of cases.

• The report highlights that vertebral fractures remain the most common osteoporotic fractures, while hip fractures continue to contribute significantly to morbidity, mortality, and healthcare burden.

• Leading Osteoporosis companies such as EnteraBio, Angitia Biopharmaceuticals, Rani Therapeutics, Amgen, UCB, Pfizer, Eli Lilly, and others are actively focused on developing advanced therapeutic solutions for Osteoporosis management.

• Promising emerging Osteoporosis therapies include EB613, RT-102, AGA2118, and other next-generation anabolic and bispecific antibody therapies designed to improve bone mineral density and fracture prevention outcomes.

Gain deeper market intelligence and strategic insights into the evolving Osteoporosis treatment landscape @ Osteoporosis Market Report: – https://www.delveinsight.com/sample-request/osteoporosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Osteoporosis Market

• Rising Aging Population and Increasing Fracture Burden: The growing elderly population worldwide, particularly postmenopausal women and aging men, is significantly increasing the prevalence of osteoporosis and fracture-related complications. Rising incidence of vertebral, hip, and wrist fractures continues to drive demand for long-term osteoporosis management solutions.

• Increasing Adoption of Advanced Bone-Building Therapies: The treatment landscape is evolving from traditional anti-resorptive agents toward advanced anabolic therapies and dual-action biologics such as EVENITY (romosozumab). Emerging therapies are expected to further improve bone formation and fracture reduction outcomes.

• Growing Focus on Early Diagnosis and Preventive Care: Increasing awareness regarding bone health, expanding screening programs, and growing utilization of bone mineral density (BMD) testing are supporting early diagnosis and preventive intervention strategies in high-risk populations.

• Emergence of Oral and Patient-Friendly Therapies: Innovative oral anabolic therapies such as EB613 are expected to improve patient compliance and accessibility compared to injectable therapies, addressing major treatment adherence challenges in osteoporosis care.

Osteoporosis Competitive Landscape

Several emerging Osteoporosis therapies are expected to intensify market competition in the coming years, including EB613 (EnteraBio), RT-102 (Rani Therapeutics), and AGA2118 (Angitia Biopharmaceuticals).

These therapies target advanced bone remodeling mechanisms through oral osteoanabolic therapy, parathyroid hormone analog delivery platforms, and bispecific antibody-mediated WNT pathway modulation. The therapies are designed to improve bone mineral density, reduce fracture risk, enhance patient compliance, and offer superior efficacy compared to conventional treatment options.

Discover more about therapies expected to capture significant Osteoporosis market share @ Emerging Osteoporosis Therapies

Recent Developments in the Osteoporosis Market

• In March 2026, Entera Bio submitted a streamlined Phase III protocol to initiate a registrational program for EB613 in postmenopausal women with osteoporosis, with topline data anticipated in the second half of 2028.

• In January 2026, Angitia Biopharmaceuticals completed enrollment in the Phase II ARTEMIS trial evaluating AGA2118 for Osteoporosis treatment, with topline data expected in 2027.

• In July 2025, Entera Bio announced that the US FDA agreed its NDA submission for EB613 could be supported by a single multinational Phase III study using total hip BMD as the primary endpoint.

• In November 2024, Angitia announced dosing of the first patient in the Phase II ARTEMIS study evaluating AGA2118, a bispecific antibody targeting sclerostin and DKK1 for osteoporosis treatment.

• Rani Therapeutics completed a pre-IND meeting with the US FDA for RT-102 and plans to initiate Phase II clinical development for the oral osteoporosis therapy candidate.

What is Osteoporosis?

Osteoporosis is a chronic skeletal disorder characterized by reduced bone mass, deterioration of bone tissue microarchitecture, and increased bone fragility, leading to a heightened risk of fractures. The disease primarily affects postmenopausal women and older adults but can also occur in men and younger individuals due to secondary causes.

Osteoporosis-related fractures most commonly occur in the hip, spine, and wrist, often resulting in severe disability, reduced quality of life, and increased mortality. Key risk factors include aging, hormonal changes, calcium and vitamin D deficiency, smoking, excessive alcohol consumption, low body weight, sedentary lifestyle, and genetic predisposition.

Osteoporosis Epidemiology Segmentation

The Osteoporosis epidemiology section provides insights into historical and forecasted patient trends across the 7MM from 2022–2036, segmented into:

• Total Prevalent Cases of Osteoporosis

• Total Diagnosed Prevalent Cases of Osteoporosis

• Gender-specific Prevalence of Osteoporosis

• Primary Osteoporosis Cases

• Secondary Osteoporosis Cases

• Incidence of Osteoporotic Fractures

• Osteoporosis-related Comorbidities

Scope of the Osteoporosis Market Report

• Therapeutic Assessment: Current marketed and emerging Osteoporosis therapies

• Osteoporosis Market Dynamics: Key market drivers, barriers, and forecast assumptions

• Key Companies: EnteraBio, Angitia Biopharmaceuticals, Rani Therapeutics, Amgen, UCB, Eli Lilly, Pfizer, and others

• Key Therapies: EB613, RT-102, AGA2118, EVENITY, PROLIA, FORTEO, DUAVEE, and others

• Competitive Intelligence Analysis: SWOT analysis, market positioning, and launch strategies

• Market Access and Reimbursement Assessment across the 7MM

• KOL Insights, Analyst Views, and Unmet Needs Analysis

Explore in-depth insights into Osteoporosis clinical development and commercial opportunities @ Osteoporosis Clinical Trials and Treatment Landscape

Table of Contents

1. Osteoporosis Market Report Introduction

2. Executive Summary of Osteoporosis

3. Osteoporosis Market Overview at a Glance

4. Osteoporosis Epidemiology and Patient Population

5. Country-specific Osteoporosis Epidemiology Analysis

6. Osteoporosis Current Treatment Landscape

7. Osteoporosis Emerging Therapies

8. Osteoporosis Market Size and Forecast Analysis

9. Osteoporosis Market Access and Reimbursement

10. Osteoporosis SWOT Analysis

11. Osteoporosis KOL Views

12. Osteoporosis Market Drivers and Barriers

13. Osteoporosis Appendix

14. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotech companies by providing comprehensive end-to-end market intelligence and strategic solutions to improve business performance. Get hassle-free access to healthcare and pharma market research reports through DelveInsight’s subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/